The DOI matches its Crossref record; 436 of the 436 references it cites were found in a registry or an index.
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Open accessAbstract
The central role of dysregulated kinase activity in the etiology of progressive disorders, including cancer, has fostered incremental efforts on drug discovery programs over the past 40 years. As a result, kinase inhibitors are today one of the most important classes of drugs. The FDA approved 73 small molecule kinase inhibitor drugs until September 2021, and additional inhibitors were approved by other regulatory agencies during that time. To complement the published literature on clinical kinase inhibitors, we have prepared a review that recaps this large data set into an accessible format for the medicinal chemistry community. Along with the therapeutic and pharmacological properties of each kinase inhibitor approved across the world until 2020, we provide the synthesis routes originally used during the discovery phase, many of which were only available in patent applications. In the last section, we also provide an update on kinase inhibitor drugs approved in 2021.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 436
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., Etienne, G., Nicolini, F. E., le Coutre, P., Clark, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00080-2 · Cited by 265
Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X., Patel, K. P., Hu, M. I.-N., Cabanillas, M. E., Behrang, A., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.599 · Cited by 265
Hu, X., Zhang, J., Xu, B., Jiang, Z., Ragaz, J., Tong, Z., Zhang, Q., Wang, X., Feng, J., Pang, D., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28829 · Cited by 264
Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 264
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Rini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., Verzoni, E., Needle, M. N., & McDermott, D. F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30735-1 · Cited by 261
Winkler, D. G., Faia, K. L., DiNitto, J. P., Ali, J. A., White, K. F., Brophy, E. E., Pink, M. M., Proctor, J. L., Lussier, J., Martin, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.017 · Cited by 260
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Mori, M., Kaneko, N., Ueno, Y., Yamada, M., Tanaka, R., Saito, R., Shimada, I., Mori, K., & Kuromitsu, S. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0470-z · Cited by 258
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., Chen, L., Dickson, C. L., Riddle Camp, J., Cardillo, T. E., et al. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.171361 · Cited by 258
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Kwitkowski, V. E., Prowell, T. M., Ibrahim, A., Farrell, A. T., Justice, R., Mitchell, S. S., Sridhara, R., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0178 · Cited by 254
Rheault, T. R., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 253
Hafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., Everley, R. A., Liu, C., Walmsley, C. S., Juric, D., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.05.005 · Cited by 250
Growney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249
Lane, H. A., Wood, J. M., McSheehy, P. M. J., Allegrini, P. R., Boulay, A., Brueggen, J., Littlewood-Evans, A., Maira, S.-M., Martiny-Baron, G., Schnell, C. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2057 · Cited by 249
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247
Le Tourneau, C., Raymond, E., & Faivre, S. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.2.341 · Cited by 247
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
Ripasudil: First Global Approval
Garnock-Jones, K. P. (2014) · Drugs · doi:10.1007/s40265-014-0333-2 · Cited by 242
Lamb, Y. N. (2019) · Drugs · doi:10.1007/s40265-019-01210-0 · Cited by 242
Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Plé, P. A., Lohmann, J.-J. M., Ogilvie, D. J., Dukes, M., Wedge, S. R., Curwen, J. O., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990345w · Cited by 241
Roth, G. J., Heckel, A., Colbatzky, F., Handschuh, S., Kley, J., Lehmann-Lintz, T., Lotz, R., Tontsch-Grunt, U., Walter, R., & Hilberg, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900431g · Cited by 237
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 236
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature · doi:10.1038/nature14119 · Cited by 234
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
van Vollenhoven, R., Takeuchi, T., Pangan, A. L., Friedman, A., Mohamed, M. F., Chen, S., Rischmueller, M., Blanco, R., Xavier, R. M., & Strand, V. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41384 · Cited by 230
Yamashita, T., Kudo, M., Ikeda, K., Izumi, N., Tateishi, R., Ikeda, M., Aikata, H., Kawaguchi, Y., Wada, Y., Numata, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-019-01642-1 · Cited by 229
Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.020 · Cited by 227
Murtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1281 · Cited by 226
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Manley, P. W., Drueckes, P., Fendrich, G., Furet, P., Liebetanz, J., Martiny-Baron, G., Mestan, J., Trappe, J., Wartmann, M., & Fabbro, D. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.008 · Cited by 225
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity
Boschelli, D. H., Ye, F., Wang, Y. D., Dutia, M., Johnson, S. L., Wu, B., Miller, K., Powell, D. W., Yaczko, D., Young, M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102250 · Cited by 217
Houghton, P. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1314 · Cited by 208
Nakamura, K., Taguchi, E., Miura, T., Yamamoto, A., Takahashi, K., Bichat, F., Guilbaud, N., Hasegawa, K., Kubo, K., Fujiwara, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4290 · Cited by 207
A precision therapy against cancers driven by KIT/PDGFRA mutations
Evans, E. K., Gardino, A. K., Kim, J. L., Hodous, B. L., Shutes, A., Davis, A., Zhu, X. J., Schmidt-Kittler, O., Wilson, D., Wilson, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1690 · Cited by 206
Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition
Gajiwala, K. S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., Kath, J. C., & Stewart, A. (2013) · Structure · doi:10.1016/j.str.2012.11.014 · Cited by 204
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective: Miniperspective
Myers, S. H., Brunton, V. G., & Unciti-Broceta, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01273 · Cited by 203
Self-citationCabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E. L., Koike, S., Shaw, A. T., Engelman, J. A., & Fujita, N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1385 · Cited by 201
Pyrotinib: First Global Approval
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-0997-0 · Cited by 201
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189391 · Cited by 200
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
Jagasia, M., Lazaryan, A., Bachier, C. R., Salhotra, A., Weisdorf, D. J., Zoghi, B., Essell, J., Green, L., Schueller, O., Patel, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02754 · Cited by 198
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
Abe, H., Kikuchi, S., Hayakawa, K., Iida, T., Nagahashi, N., Maeda, K., Sakamoto, J., Matsumoto, N., Miura, T., Matsumura, K., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200004g · Cited by 196
Progress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 194
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Bender, A. T., Gardberg, A., Pereira, A., Johnson, T., Wu, Y., Grenningloh, R., Head, J., Morandi, F., Haselmayer, P., & Liu-Bujalski, L. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107037 · Cited by 193
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., & Araie, M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.016 · Cited by 190
Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., Helms, W., Leong, R., Song, P., Pan, Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3157 · Cited by 190
Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
Talpaz, M., & Kiladjian, J.-J. (2021) · Leukemia · doi:10.1038/s41375-020-0954-2 · Cited by 188
Ou, S.-H. I. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s19045 · Cited by 187
Lin, C.-W., Sherman, B., Moore, L. A., Laethem, C. L., Lu, D.-W., Pattabiraman, P. P., Rao, P. V., deLong, M. A., & Kopczynski, C. C. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0023 · Cited by 187
COVID-19 and readjusting clinical trials
van Dorn, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31787-6 · Cited by 184
Lapatinib: Current Status and Future Directions in Breast Cancer
Moy, B., & Goss, P. E. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1047 · Cited by 180
Moy, B., Kirkpatrick, P. N., Kar, S., & Goss, P. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2332 · Cited by 180
Structural basis for the action of the drug trametinib at KSR-bound MEK
Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., Scopton, A. P., & Dar, A. C. (2020) · Nature · doi:10.1038/s41586-020-2760-4 · Cited by 178
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., Cherian, M. A., Sardesai, S., & Wesolowski, R. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s253232 · Cited by 177
MAP kinase signaling and inhibition in melanoma
Sullivan, R. J., & Flaherty, K. T. (2012) · Oncogene · doi:10.1038/onc.2012.345 · Cited by 173
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 172
Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H. I., Gulrajani, M., Krantz, F., Mantel, R., Smith, L. L., McClanahan, F., Harrington, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0463 · Cited by 172
Entrectinib: First Global Approval
Al-Salama, Z. T., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01177-y · Cited by 172
Lin, Q., Meloni, D., Pan, Y., Xia, M., Rodgers, J., Shepard, S., Li, M., Galya, L., Metcalf, B., Yue, T.-Y., et al. (2009) · Organic Letters · doi:10.1021/ol900350k · Cited by 171
A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity
Levinson, N. M., & Boxer, S. G. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1404 · Cited by 171
Somoza, J. R., Koditek, D., Villaseñor, A. G., Novikov, N. Y., Wong, M. H. L., Liclican, A. C., Xing, W., Lagpacan, L., Wang, R., Schultz, B. E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634683 · Cited by 170
Olmutinib: First Global Approval
Kim, E. S. (2016) · Drugs · doi:10.1007/s40265-016-0606-z · Cited by 170
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Wu, J., Savooji, J., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0251-8 · Cited by 169
Rice, K. D., Aay, N., Anand, N. K., Blazey, C. M., Bowles, O. J., Bussenius, J., Costanzo, S., Curtis, J. K., Defina, S. C., Dubenko, L., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300049d · Cited by 167
Petrov, K. G., Zhang, Y.-M., Carter, M., Cockerill, G. S., Dickerson, S., Gauthier, C. A., Guo, Y., Mook, R. A., Rusnak, D. W., Walker, A. L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.090 · Cited by 166
Axitinib for the Management of Metastatic Renal Cell Carcinoma
Escudier, B. J., & Gore, M. E. (2011) · Drugs in R&D · doi:10.2165/11591240-000000000-00000 · Cited by 165
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
Park, I.-K., Mundy-Bosse, B., Whitman, S. P., Zhang, X., Warner, S. L., Bearss, D. J., Blum, W., Marcucci, G., & Caligiuri, M. A. (2015) · Leukemia · doi:10.1038/leu.2015.147 · Cited by 164
Kinoshita, K., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Miyagi, T., Kobayashi, T., Takanashi, K., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.021 · Cited by 164
Dacomitinib: First Global Approval
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-1028-x · Cited by 163
Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 163
Yasuda, H., de Figueiredo-Pontes, L. L., Kobayashi, S., & Costa, D. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182570919 · Cited by 161
Wöhrle, S., Henninger, C., Bonny, O., Thuery, A., Beluch, N., Hynes, N. E., Guagnano, V., Sellers, W. R., Hofmann, F., Kneissel, M., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1810 · Cited by 160
Synthetic Approaches to the New Drugs Approved During 2015
Flick, A. C., Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., & O’Donnell, C. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00010 · Cited by 159
Erdafitinib: First Global Approval
Markham, A. (2019) · Drugs · doi:10.1007/s40265-019-01142-9 · Cited by 159
Liu, P. C. C., Koblish, H., Wu, L., Bowman, K., Diamond, S., DiMatteo, D., Zhang, Y., Hansbury, M., Rupar, M., Wen, X., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231877 · Cited by 158
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 157
Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases
Barvian, M. R., Boschelli, D. H., Cossrow, J., Dobrusin, E. M., Fattaey, A., Fritsch, A., Fry, D. W., Harvey, P., Keller, P. R., Garrett, M. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000271k · Cited by 157
Moulder, S. L., Borges, V. F., Baetz, T. D., McSpadden, T., Fernetich, G., Murthy, R. K., Chavira, R., Guthrie, K., Barrett, E., & Chia, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1496 · Cited by 157
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Gilteritinib: potent targeting of FLT3 mutations in AML
Levis, M. J., & Perl, A. E. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000174 · Cited by 154
Molecular Mechanism for the Regulation of Rho-Kinase by Dimerization and Its Inhibition by Fasudil
Yamaguchi, H. Q., Kasa, M., Amano, M., Kaibuchi, K., & Hakoshima, T. (2006) · Structure · doi:10.1016/j.str.2005.11.024 · Cited by 152
Thornton, K. A., Kim, G., Maher, V. E., Chattopadhyay, S., Tang, S. W., Moon, Y. J., Song, P., Marathe, A., Balakrishnan, S., Zhu, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0411 · Cited by 152
Rewcastle, G. W., Palmer, B. D., Bridges, A. J., Showalter, H. D. H., Sun, L., Nelson, J. M., McMichael, A., Kraker, A. J., Fry, D. W., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950692f · Cited by 150
Kubo, K., Shimizu, T., Ohyama, S.-I., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N. K., Takahashi, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm030427r · Cited by 150
Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 150
Kantarjian, H., Jabbour, E., Grimley, J., & Kirkpatrick, P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2135 · Cited by 149
Encorafenib and Binimetinib: First Global Approvals
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 149
Neratinib: First Global Approval
Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0811-4 · Cited by 148
Lorlatinib: First Global Approval
Syed, Y. Y. (2019) · Drugs · doi:10.1007/s40265-018-1041-0 · Cited by 147
Fabbro, D., Buchdunger, E., Wood, J., Mestan, J., Hofmann, F., Ferrari, S. M., Mett, H., O’Reilly, T., & Meyer, T. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00005-4 · Cited by 145
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01482-5 · Cited by 145
Metzger, G. J. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.023 · Cited by 144
Brigatinib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0776-3 · Cited by 143
Atkins, M. B., Jones, C. A., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2012 · Cited by 143
Tan, F., Shen, X., Wang, D., Xie, G., Zhang, X., Ding, L., Hu, Y., He, W., Wang, Y., & Wang, Y. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.023 · Cited by 139
Bukowski, R. M., Yasothan, U., & Kirkpatrick, P. N. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3073 · Cited by 139
Management of toxicity to isoform α-specific PI3K inhibitors
Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137
Tanihara, H., Inoue, T., Yamamoto, T., Kuwayama, Y., Abe, H., Fukushima, A., Suganami, H., & Araie, M. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12829 · Cited by 137
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Giles, F. J., O'Dwyer, M. E., & Swords, R. T. (2009) · Leukemia · doi:10.1038/leu.2009.111 · Cited by 135
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof
Davis, R. R., Li, B., Yun, S. Y., Chan, A., Nareddy, P. R., Gunawan, S., Ayaz, M., Lawrence, H. R., Reuther, G. W., Lawrence, N. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01952 · Cited by 135
Markham, A., & Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01331-x · Cited by 134
O’Reilly, T., & McSheehy, P. M. J. (2010) · Translational Oncology · doi:10.1593/tlo.09277 · Cited by 133
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Scott, W. J., Hentemann, M. F., Rowley, R. B., Bull, C. O., Jenkins, S., Bullion, A. M., Johnson, J. S., Redman, A. M., Robbins, A. H., Esler, W. P., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600148 · Cited by 129
New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Aparicio-Gallego, G., Blanco, M., Figueroa, A., García‐Campelo, R., Valladares‐Ayerbes, M., Grande-Pulido, E., & Antón-Aparicio, L. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1124 · Cited by 128
STI-571: an anticancer protein-tyrosine kinase inhibitor
Roskoski, R. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.055 · Cited by 127
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01291-2 · Cited by 126
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Ravandi, F., Kantarjian, H., Faderl, S., Garcia-Manero, G., O’Brien, S., Koller, C., Pierce, S., Brandt, M., Kennedy, D., Cortes, J., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.10.001 · Cited by 125
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
Poratti, M., & Marzaro, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.064 · Cited by 123
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 123
Inhibition of c-Kit by tyrosine kinase inhibitors
Galanis, A., & Levis, M. J. (2014) · Haematologica · doi:10.3324/haematol.2014.117028 · Cited by 121
Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 119
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso‐Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 119
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115
Tanihara, H. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.323 · Cited by 118
ZHAO, J., ZHOU, D., GUO, J., REN, Z., ZHOU, L., WANG, S., XU, B., & WANG, R. (2006) · Neurologia medico-chirurgica · doi:10.2176/nmc.46.421 · Cited by 117
Synthetic approaches to the 2014 new drugs
Flick, A. C., Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., & O’Donnell, C. J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.004 · Cited by 117
A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
Bankston, D. D., Dumas, J., Natero, R., et al. (2002) · Organic Process Research & Development · doi:10.1021/op020205n · Cited by 115
Steegmann, J. L., Cervantes, F., le Coutre, P., Porkka, K., & Saglio, G. N. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.695779 · Cited by 115
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01318-8 · Cited by 113
Zhou, M., Chen, X., Zhang, H., Xia, L., Tong, X., Zou, L., Hao, R., Pan, J., Zhao, X. Q., Chen, D., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0383-7 · Cited by 112
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 111
H-Series Protein Kinase Inhibitors and Potential Clinical Applications
Ono-Saito, N., Niki, I., & Hidaka, H. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00070-9 · Cited by 108
Patani, H., Bunney, T., Thiyagarajan, N., Norman, R., Ogg, D., Breed, J., Ashford, P., Potterton, A., Edwards, M., Williams, S. V., et al. (2016) · OncoTarget · doi:10.18632/oncotarget.8132 · Cited by 108
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Sturdivant, J. M., Royalty, S. M., Lin, C., Moore, L. A., Yingling, J. D., Laethem, C. L., Sherman, B. W., Heintzelman, G. R., Kopczynski, C., & deLong, M. A. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.104 · Cited by 108
Li, Z., Jiang, K., Zhu, X., Lin, G., Song, F., Zhao, Y., Piao, Y., Liu, J., Cheng, W., Bi, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.015 · Cited by 107
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01347-3 · Cited by 106
Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition
Lü, H., & Schulze‐Gahmen, U. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600388 · Cited by 104
Effects of K-115, a Rho-Kinase Inhibitor, on Aqueous Humor Dynamics in Rabbits
Isobe, T., Mizuno, K., Kaneko, Y., Ohta, M., Koide, T., & Tanabe, S. (2014) · Current Eye Research · doi:10.3109/02713683.2013.874444 · Cited by 104
Ribociclib: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0742-0 · Cited by 104
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01427-4 · Cited by 104
Boerma, M., Fu, Q., Wang, J., Loose, D. S., Bartolozzi, A., Ellis, J. L., McGonigle, S., Paradise, E., Sweetnam, P. M., Fink, L. M., et al. (2008) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32830b2891 · Cited by 103
Liclican, A. C., Serafini, L., Xing, W., Czerwieniec, G. A., Steiner, B. H., Wang, T., Brendza, K. M., Lutz, J. D., Keegan, K. S., Ray, A. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129531 · Cited by 101
Baillache, D. J., & Unciti‐Broceta, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00227e · Cited by 101
Self-citationKang, C. (2021) · Drugs · doi:10.1007/s40265-021-01567-1 · Cited by 101
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 100
Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
Zhao, Q., Shentu, J., Xu, N., Zhou, J., Yang, G., Yao, Y., Tan, F., Liu, D., Wang, Y., & Zhou, J. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.007 · Cited by 99
Kim, S., Tiedt, R., Loo, A. T., Horn, T. L., Delach, S. M., Kovats, S., Haas, K., Engstler, B. S., Cao, Z. A., Pinzon-Ortiz, M. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26215 · Cited by 98
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
Lebwohl, D., Anak, Ö., Sahmoud, T., Klimovsky, J., Elmroth, I., Haas, T., Posluszny, J. A., Saletan, S., & Berg, W. J. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12122 · Cited by 97
Erlotinib in the treatment of advanced pancreatic cancer
Ko, A. H. (2008) · Biologics · doi:10.2147/btt.s1832 · Cited by 96
Netarsudil Ophthalmic Solution 0.02%: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0877-7 · Cited by 96
Fostamatinib: First Global Approval
Markham, A. (2018) · Drugs · doi:10.1007/s40265-018-0927-1 · Cited by 96
Peficitinib: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01131-y · Cited by 96
Synthetic approaches to the 2013 new drugs
Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., Flick, A. C., & O’Donnell, C. J. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.056 · Cited by 93
A Novel Approach to the Discovery of Small‐Molecule Ligands of CDK2
Martin, M. P., Alam, R., Betzi, S., Ingles, D. J., Zhu, J., & Schönbrunn, E. (2012) · ChemBioChem · doi:10.1002/cbic.201200316 · Cited by 93
Ruxolitinib: A New JAK1/2 Inhibitor That Offers Promising Options for Treatment of Myelofibrosis
Ostojić, A., Vrḫovac, R., & Verstovšek, S. (2011) · Future Oncology · doi:10.2217/fon.11.81 · Cited by 93
Sumi, N. J., Kuenzi, B. M., Knezevic, C. E., Rix, L. L. R., & Rix, U. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00368 · Cited by 93
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
Kinoshita, K., Kobayashi, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Hattori, K., Miyagi, T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200652u · Cited by 89
Hamaguchi, H., Amano, Y., Moritomo, A., Shirakami, S., Nakajima, Y., Nakai, K., Nomura, N., Ito, M., Higashi, Y., & Inoue, T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.005 · Cited by 86
Anderson, E. J., Mollon, L. E., Dean, J. L., Warholak, T. L., Aizer, A. A., Platt, E., Tang, D. H., & Davis, L. E. (2020) · International Journal of Breast Cancer · doi:10.1155/2020/3759179 · Cited by 86
Dhillon, S., & Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01439-0 · Cited by 86
Synthetic approaches to the 2009 new drugs
Liu, K. K. ‐., Sakya, S. M., O’Donnell, C. J., Flick, A. C., & Li, J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.038 · Cited by 85
Kawase, T., Nakazawa, T., Eguchi, T., Tsuzuki, H., Ueno, Y., Amano, Y., Suzuki, T., Mori, M., & Yoshida, T. (2019) · Oncotarget · doi:10.18632/oncotarget.27222 · Cited by 85
Liu, G. J., Wang, Z. J., Wang, Y. F., Xu, L., Wang, X. L., Liu, Y., Luo, G. J., He, G. H., & Zeng, Y. J. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1100-x · Cited by 84
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 84
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Wu, L., Zhang, C., He, C., Qian, D., Lü, L., Sun, Y., Xu, M., Zhuo, J., Liu, P. C. C., Klabe, R. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00713 · Cited by 84
Zhang, Y., Zou, J.-Y., Wang, Z., & Wang, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s215533 · Cited by 82
Kwak, J., Kim, S., Oh, S. J., Zang, D. Y., Kim, H., Kim, J., Do, Y. R., Kim, H. J., Park, J. S., Choi, C. W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0957 · Cited by 81
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
Salgia, R., Sattler, M., Scheele, J., Stroh, C., & Felip, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102022 · Cited by 76
Wang, Y. D., Miller, K., Boschelli, D. H., Ye, F., Wu, B., Floyd, M. B., Powell, D. W., Wissner, A., Weber, J. M., & Boschelli, F. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00493-5 · Cited by 73
Smith, A. B., Condon, S. M., McCauley, J. A., Leazer, J. L., Leahy, J. W., & Maleczka, R. E. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963066w · Cited by 73
Synthetic Approaches to the New Drugs Approved During 2017
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., & O’Donnell, C. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00196 · Cited by 73
Zhang, L., Li, M., Liu, B., Zhang, Y., Zhu, H., Cui, J., Sun, A., Hu, Y., Jin, J., Jiang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1600 · Cited by 72
Kim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J., Sohn, S. K., Park, J. S., Jeong, S. H., Kim, H., Kim, Y.-K., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096776 · Cited by 71
Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia
Vangapandu, H. V., Jain, N., & Gandhi, V. V. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312338 · Cited by 71
Synthetic Approaches to New Drugs Approved During 2016
Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 71
New drug approvals for 2019: Synthesis and clinical applications
Yuan, S., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112667 · Cited by 69
Ceritinib: First Global Approval
Dhillon, S., & Clark, M. (2014) · Drugs · doi:10.1007/s40265-014-0251-3 · Cited by 68
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance
Kesarwani, M., Huber, E., Kincaid, Z., Evelyn, C. R., Biesiada, J., Rance, M., Thapa, M. B., Shah, N. P., Meller, J., Zheng, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep14538 · Cited by 68
Noji, S., Hara, Y., Miura, T., Yamanaka, H., Maeda, K., Hori, A., Yamamoto, H., Obika, S., Inoue, M., Hase, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00450 · Cited by 68
Synthetic Approaches to New Drugs Approved during 2018
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., DeForest, J. C., Morse, P., Mahapatra, S., & O’Donnell, C. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00345 · Cited by 66
Villaseñor, A. G., Kondru, R. K., Ho, H., Wang, S., Papp, E., Shaw, D. E., Barnett, J. W., Browner, M. F., & Kuglstatter, A. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00785.x · Cited by 65
Deadman, B. J., Hopkin, M. D., Baxendale, I. R., & Ley, S. V. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob27003j · Cited by 65
Sun, J. X., Zager, J. S., & Eroglu, Z. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171693 · Cited by 61
Grünwald, V., Voss, M. H., Rini, B. I., Powles, T. B., Albiges, L. K., Giles, R. H., & Jonasch, E. W. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0949-9 · Cited by 60
A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Temps, C., Lietha, D., Webb, E. R., Li, X., Dawson, J. C., Muir, M., MacLeod, K. G., Valero, T., Munro, A. F., Contreras‐Montoya, R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0613 · Cited by 57
Self-citationAlectinib: A Review in Advanced, ALK-Positive NSCLC
Paik, J., & Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0952-0 · Cited by 56
Nemunaitis, J. J., Bauer, S., Blay, J., Choucair, K., Gelderblom, H. A. J., George, S., Schöffski, P., von Mehren, M., Zalcberg, J. R., Achour, H., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0633 · Cited by 56
Gibson, K. H., Grundy, W., Godfrey, A. A., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10059-2 · Cited by 55
Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
Lamb, Y. N., & Scott, L. J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0519-0 · Cited by 54
Synthetic approaches to the 2012 new drugs
Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Sakya, S. M., Flick, A. C., & O’Donnell, C. J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.017 · Cited by 52
Chen, Q., Ouyang, D., Anwar, M., Xie, N., Wang, S., Fan, P., Qian, L., Chen, G., Zhou, E., Guo, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00811 · Cited by 52
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
Zabriskie, M. S., Vellore, N. A., Gantz, K. C., Deininger, M. W., & O’Hare, T. (2015) · Leukemia · doi:10.1038/leu.2015.42 · Cited by 49
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
Chang, E., Weinstock, C., Zhang, L., Fiero, M. H., Zhao, M., Zahalka, E., Ricks, T. K., Zirkelbach, J. F., Qiu, J., Yu, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2334 · Cited by 49
Lipase-Catalyzed Regioselective Esterification of Rapamycin: Synthesis of Temsirolimus (CCI-779)
Gu, J., RUPPEN, M. E., & Cai, P. (2005) · Organic Letters · doi:10.1021/ol0514395 · Cited by 47
Structure of FKBP12.6 in complex with rapamycin
Deivanayagam, C. C. S., Carson, M., Thotakura, A., Narayana, S. V. L., & Chodavarapu, R. S. (2000) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444999016571 · Cited by 47
Metzger, O., Leone, J. P., Li, T., Tan‐Wasielewski, Z., Trippa, L., Barry, W. T., Younger, J., Lawler, E., Walker, L. N., Freedman, R. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.014 · Cited by 46
Cheson, B. D., O'Brien, S. M., Ewer, M. S., Goncalves, M. D., Farooki, A., Lenz, G., Yu, A. F., Fisher, R. I., Zinzani, P. L., & Dreyling, M. H. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.11.021 · Cited by 45
Cited by
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348
“As using ATP competitors is a well-established strategy for targeting kinases 57 , we selected the ATP-binding site as a pocket for compound generation.”
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
Harnessing systematic protein–ligand interaction fingerprints for drug discovery
Zhao, Z., & Bourne, P. E. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.004 · Cited by 41
Metadata
- Authors
- Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-08
- Volume
- 65
- Issue
- 2
- Pages
- 1047-1131
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3203420675
- Cited by
- 265
- References
- 436
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.